Clinical studies reveal extended survival in diffuse midline glioma patients receiving ONC201 treatment; research also explains the underlying mechanism of the drug’s success.
For the first time, a potential drug candidate has been identified by researchers that show promise in improving outcomes for patients suffering from a specific type of childhood brain tumor that currently lacks effective treatment options. The compound, named ONC201, was observed to nearly double the survival rates for patients diagnosed with diffuse midline glioma (DMG) or diffuse intrinsic pontine glioma (DIPG) when compared to prior patient outcomes.
The findings are reported by an international team of researchers led by the University of Michigan Health Rogel Cancer Center and the Chad Carr Pediatric Brain Tumor Center.
In addition to reporting on the results of two early-stage clinical trials, the paper reveals the underlying mechanisms behind the compound’s success in these tumors. The paper is published in Cancer Discovery, a journal of the American Association for Cancer Research.
“It’s an incredibly difficult tumor to treat,” said senior author Carl Koschmann, M.D., associate professor of pediatric neuro-oncology and clinical scientific director of the Chad Carr Pediatric Brain Tumor Center at Michigan Medicine. “Prior to this study, there have been more than 250 clinical trials that have not been able to improve outcomes. This is a major crack in the armor.”
A series of brain scans show a tumor shrinking in response to ONC201. Credit: Michigan Medicine
In two clinical trials testing ONC201 in a total of 71 patients with H3K27M-mutated diffuse midline gliomas, the median overall survival was nearly 22 months for tumors that had not recurred at the time of enrollment. Almost a third of the patients lived longer than two years.
ONC201 took an unusual path to a clinical trial. Initially designed to target dopamine receptors, which are upregulated in many different tumors, researchers saw that the drug passes the blood-brain barrier, one of the biggest challenges to designing drugs for brain tumors. Initial trials in glioblastoma were not successful, but a small number of patients with DMG that carried the H3K27M mutation had more promising results. Without understanding why it worked better in these patients, a phase 1 trial was started in children and young adults with H3K27M-mutated DMG.
Meanwhile, Koschmann and co-author Sriram Venneti, M.D., Ph.D., were trying to figure out what was happening in these tumor cells
Through the trial, they collected cerebrospinal fluid from patients. They used this fluid to analyze metabolic changes and found ONC201 got into the tumor cells and affected mitochondria. Patients who responded to the drug had an increase in a metabolite called L-2HG produced by tumor cells.
Koschmann called the finding “very much unexpected.” The team found that increased L-2HG reversed tumor-defining epigenetic signals causing tumor cells to differentiate more and divide less. The longer patients were on ONC201, the more tumors exhibited these epigenetic reversals.
“This could explain why this patient population was responding so well to the drug because it had this specific epigenetic abnormality that could be turned off by ONC201. The tumors have an epigenetic change caused by the H3K27M mutation and ONC201 metabolically undoes that change,” said Venneti, associate professor of pathology and pediatrics and scientific research director of the Chad Carr Pediatric Brain Tumor Center at Michigan Medicine.
Additional clinical trials are currently underway, including testing ONC201 in combination with other therapies. Researchers at U-M’s Chad Carr Pediatric Brain Tumor Center are also continuing to look at ways to overcome resistance to ONC201 by using drug combinations.
Koschmann notes that even a near-doubling of survival is not enough for families of patients with this diagnosis, as the tumor remains very lethal. But he hopes this first step will lead to bigger leaps in the future.
“For now we have this patient population that didn’t have a drug before, and now we see many of the tumors responding. We have a platform to build on and we can also explain why it’s working,” he said.
“We are really excited about this study and envision ONC201 becoming the standard of care for these patients in the near future,” Venneti said.
News
Why More People in Their 30s Are Suddenly Getting Colon Cancer
A major Swiss study found that colorectal cancer is becoming increasingly common in adults under 50, even as rates decline in older age groups. Researchers in Switzerland have identified a concerning trend: while colorectal [...]
Researchers Compare MS Models to Human Tissue in Search for Better Therapies
Researchers identified key differences between two widely used multiple sclerosis models, showing how each can better study myelin damage, immune responses, and repair. The findings may improve efforts to develop treatments that restore lost [...]
Scientists Discover Genetic “Off Switch” That Supercharges CAR T Cells Against Cancer
A new study reveals a possible way to make CAR T-cell therapy more durable and effective by targeting a single gene-regulating protein. CAR T-cell therapy is widely seen as a breakthrough in personalized cancer [...]
New Vitamin B12-Based Therapy Could Change How Brain Cancer Is Treated
Researchers have identified a vitamin B12–based compound that appears capable of crossing the blood–brain barrier and selectively accumulating in glioblastoma tissue. For decades, one of the biggest problems in brain cancer treatment has had [...]
Simple Fiber Supplement Cuts Knee Arthritis Pain in Just 6 Weeks, Study Finds
A daily inulin supplement may help reduce knee osteoarthritis pain while revealing a possible link between gut health, muscle function, and pain sensitivity. For millions of people living with knee osteoarthritis, managing chronic pain [...]
This Common Vitamin May Help Stop Prediabetes From Turning Into Diabetes
Vitamin D may help prevent type 2 diabetes in people with specific genetic variations, offering a possible path toward personalized diabetes prevention. More than 40% of U.S. adults have prediabetes, a condition in which [...]
Ebola, hantavirus: Is the world prepared for the next pandemic?
Funding cuts to health research and a growing antivaccine movement are making it harder than ever to respond to viruses. The World Health Organization (WHO) has declared that an Ebola outbreak in Uganda and [...]
May 2026 Healthcare News and Trends: Market Signals That Matter
Artificial intelligence is dominating headlines, telehealth has settled into a new normal, and digital health continues to promise transformation. However, much of what is being discussed in healthcare today reflects potential rather than reality. [...]
Scientists Rewire Donor Stem Cells To Outsmart Aggressive Blood Cancers
Researchers have tested a gene-edited stem cell transplant designed to shield healthy blood-forming cells from powerful cancer-targeting immunotherapies. For patients with highly aggressive blood cancers, stem cell transplantation can offer a rare chance at [...]
Recent Digital Health Trends, Insights and News – May 2026
Last month marked continued progress as digital health moves into its next phase — from AI expanding into drug discovery and core infrastructure to new federal pathways accelerating device access and home-based care. Together, [...]
Cancer Mystery Solved: Scientists Discover How Melanoma Becomes “Immortal”
Scientists have uncovered a previously overlooked mechanism that may help melanoma cells become effectively “immortal.” Cancer cells face a major problem before they can become deadly: They have to figure out how to stop [...]
How Visual Neurons Organize Thousands of Synaptic Inputs
Summary: A new study uncovered the organizational rules that determine how neurons in the primary visual cortex process information. By imaging both the cell bodies (soma) and the individual synapses (on dendritic spines) of [...]
Scientists Just Found a Surprising Way To Destroy “Forever Chemicals”
Scientists have uncovered a new mechanism that may help break down highly persistent PFAS pollutants. PFAS have earned the nickname “forever chemicals” for a reason. These industrial compounds are so chemically durable that they [...]
Scientists Discover Cheap Material That Kills Deadly Superbugs
A new sulfur-rich antimicrobial polymer shows strong effectiveness against fungal and bacterial pathogens and may offer an affordable solution to antimicrobial resistance. Antimicrobial resistance is creating growing challenges for both healthcare and food production, [...]
What to Know About Cicada, or BA.3.2, the Latest SARS-CoV-2 Variant Under Monitoring
Like periodical cicadas, the insects for which it is nicknamed, SARS-CoV-2 Omicron subvariant BA.3.2 is only just beginning to emerge after lying low for an extended period since it first appeared. Although it was [...]
Scientists Say This Simple Supplement May Actually Reverse Heart Disease
Scientists in Japan say a common supplement may actually help “unclog” certain diseased heart arteries from the inside out. A simple food supplement sold in Japan may have helped reverse a dangerous form of [...]
